Shanghai Henlius Biotech, Inc：POHERDY®Pertuzumab Injection received marketing approval.
Recently (on May 29), an announcement was issued stating that Pertuzumab Injection (brand name: POHERDY®), a product of its controlled subsidiary, has been approved for marketing. The product is indicated for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, as well as for the treatment of metastatic breast cancer, fully covering all the indications of the reference product (originator pertuzumab) approved in China.
Pertuzumab was originally developed by Roche Holding AG and first entered the Chinese market in 2018. According to available data, the total sales of antineoplastic drugs (chemical drugs and biologics) across all terminal channels in 2025 exceeded RMB 130 billion. Among them, Pertuzumab Injection delivered an outstanding performance, achieving annual sales of RMB 2.44 billion and securing a position among the top 10 antineoplastic biologics in China, highlighting the sustained value of this therapeutic segment.
POHERDY®, together with FOSUN Pharma’s independently developed HERCESSI® , forms the first domestic “Trastuzumab + Pertuzumab” dual-target combination approved in China, the United States, and the European Union. This further solidifies FOSUN Pharma’s leading position with a “full-course, full-scope, and global” strategy in the field of breast cancer treatment.
Buy POHERDY® (Pertuzumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
